NEW YORK, August 11, 2017 /PRNewswire/ --
If you want a Stock Review on DXCM, NVDQ, BIOC, or EXAS then come overto http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, August 10, 2017, US markets saw broad based losses with eight out of nine sectors finishing the trading sessions
On Thursday, shares in San Diego, California headquartered DexCom Inc. recorded a trading volume of 1.65 million shares, which was above their three months average volume of 1.17 million shares. The stock ended the session 2.43% lower at $69.80. The Company's shares have gained 16.92% on an YTD basis. The stock is trading below its 50-day moving average by 2.63%. Moreover, shares of DexCom, which together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have a Relative Strength Index (RSI) of 47.41. Visit us today and download your complete report on DXCM for free at:
Mississauga, Canada headquartered Novadaq Technologies Inc.'s stock closed the day 0.04% lower at $11.66 with a total trading volume of 929,827 shares. The Company's shares have advanced 52.62% in the previous three months, 8.87% over the last twelve months, and 64.46% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 12.19% and 40.20%, respectively. Additionally, shares of Novadaq Technologies, which develops, manufactures, and markets fluorescence imaging products for use by surgeons in the operating room and other clinical settings in the US and internationally, have an RSI of 82.90.
On July 13th, 2017, research firm RBC Capital Markets downgraded the Company's stock rating from 'Outperform' to 'Sector Perform' while revising its previous target price from $12 a share to $11.75 a share. The complimentary research report on NVDQ can be accessed at:
Shares in San Diego, California headquartered Biocept Inc. recorded a trading volume of 812,524 shares, which was above their three months average volume of 539.73 thousand shares. The stock ended yesterday's trading session 4.24% higher at $1.45. The Company's shares have advanced 86.97% on an YTD basis. The stock is trading above its 50-day moving average by 3.54%. Furthermore, shares of Biocept, which develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample, have an RSI of 56.88. Register for free on DailyStockTracker.com and download the research report on BIOC at:
Madison, Wisconsin headquartered Exact Sciences Corp.'s stock finished Thursday's session 0.54% lower at $37.05 with a total trading volume of 1.28 million shares. The Company's shares have advanced 90.49% in the past twelve months and 177.32% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.23% and 50.25%, respectively. Additionally, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers in the US, have an RSI of 47.62.
On July 26th, 2017, research firm Lake Street reiterated its 'Hold' rating on the Company's stock with an increase of the target price from $30 a share to $41 a share. Get free access to your research report on EXAS at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...
Dizziness is a feeling of being faint or unsteady whereas Vertigo is a feeling that you or your ...View All